Manufacturing DPIs: IMA Active and Medochemie driving inhalation innovation.

IMA Active and Medochemie combined the dosator technology and the direct net weight to achieve optimal low-dose Dry Powder Inhalers.

When developing new pharmaceutical products in DPI form, industrial manufacturing aspects must be considered from the very beginning to shorten the scale-up and optimisation of the final manufacturing process, as well as to achieve a more efficient and cost effective production. Precise micro-dosing, weight control and ease of device assembly are all issues that must be faced at an early stage.
IMA draws on its extensive expertise to provide the most advanced solutions for DPI processing and assembly. Direct weight control performed in line on each single capsule or device, both before and after filling. Absence of mechanical powder compression for improved airway intake. Accurate micro-dosing and automatic feedback and adjustment.
This study investigates optimal process parameters for micro-dose DPIs achieved by the dosator technology. The study proves that a major advantage of using this technology for processing DPIs is that the dosators can be accurately adjusted without any need to compress or aspirate the powder. Maintaining the free-flowing properties of the dispended powder within the capsule better ensures the release of powder from the capsule into the inhaler when the capsule is pierced, thereby better controlling both the emitted dose and the fine particle fraction of the dose discharged from the DPI.

Introduction

In 1948, the first commercial dry powder inhalation device was launched on the market. This first technology seems archaic by today’s standards: a deep inward breath would cause a ball to strike a cartridge containing powder and shake the powder into the airstream. Since then, changes in the drug delivery market and regulatory pressures have driven innovation of DPIs forward. It is estimated by the WHO that, worldwide, some 300 million people suffer from asthma and 240 million people suffer from chronic obstructive disease (COPD). DPIs represent 50% of the total asthma/COPD market by value worldwide.
The latest patient-focused studies using DPIs indicated that the expectations regarding this technology have evolved. Patients and pneumologists are now increasingly focusing on convenience and ease of use, favouring a compact design. Indeed, DPIs have shown great promise in their ability to deliver drugs reliably and effectively, and novel designs can ensure that future cost, compliance and safety challenges are overcome. Some of the performance characteristics essential to DPIs are related to dose delivery, fine particle fraction content and performance levels at varying airflows. These characteristics can differ from one powder formulation to another, and some fine tuning of either device or formulation or a combination of both may be necessary to achieve optimal performance. Micro-dosing DPIs takes this challenge to extremes.
IMA Active and Medochemie have joined forces in order to achieve optimal micro-dose Dry Powder Inhalers by combining the dosator technology and the direct net weight control both in a table-top device and in an industrial production scale capsule filler.

Table 1: technological characteristics of the two kinds of powder mixes: Inhalac 251 (Meggle, Germany) and Respitose (DFE, Germany) with 4% Lactochem microfine lactose each.

Aim of the study

The aim of the study was to explore the best process parameters to achieve the 5.5 mg dose of a powder mix including a first Lactose type as carrier and a second one (4% in concentration by weight) of micro-fine lactose as API simulator. The process was carried out as a first approach in a table-top capsule filling device (MINIMA, IMA, Italy) and then up scaled to an industrial production scale capsule filling machine (ADAPTA with 100% gravimetric net weight control, IMA, Italy). Two types of Lactose were compared from different suppliers.

Materials

Components of the tested formulations are described below:

A) Blend of placebo powder composed of Inhalac 251 (Meggle, Germany) and 4% in concentration of Lactochem microfine lactose (DFE, Germany).
B) Blend of placebo powder composed of Respitose (DFE, Germany) and 4% in concentration of Lactochem microfine lactose (DFE, Germany).

For the execution of the tests, HPMC capsules size 3 produced were used.

Methods

The MINIMA and ADAPTA capsule fillers are designed to process micro-dose Dry Powder Inhalers. MINIMA is a table-top capsule filler designed to dose solid products in hard capsules. Extremely precise and with a single dosator, MINIMA can be equipped with the same dosing devices applied on IMA production machines. MINIMA comes factory-preset for use with Dry Powder Inhalers, thus being an efficient system for inhalation product research, development, optimisation and protocole validation.
The ADAPTA capsule filling machine covers medium and very high-speed production requirements and features exceptional design flexibility. Fitted with the 100% gravimetric net weight control, ADAPTA ensures maximum dosing precision and reliability even at very high speed. On the MINIMA machine, the target dosages of 5.5 mg, 15 mg and 25 mg was achieved with both formulations. Each lot consists of 20 samples. Reliability and consistency were assessed by replicating the acquisitions three times for each lot.
The second step of the study was to up scale the experience gained on the bench top machine to the production equipment. Since the target dose was 5.5 mg the main work was concentrated on this target with both preparations. 100,000 capsules were produced with ADAPTA with 100% gravimetric net weight control for each blend.
To determine the net weight of the samples dosed with MINIMA, the macro-analytical electronic scale Sartorius was used. Weighing range: 220 g, accuracy: 0.1 mg. To check the net weight of the samples dosed with the capsule filling machine, the total filling control system of ADAPTA was used.

Results

The tests on MINIMA demonstrated that both formulations gave good results in terms of workability and tolerance obtained. No significant differences were observed by the operator. Both formulations demonstrated good behavior even on the machine ADAPTA with 100% gravimetric net weight control: no seizing and no empty capsules produced. It was confirmed that for 5.5 mg dosing the range between the minimum and maximum weight value in the table-top capsule filler was always lower than 1 mg.
The results obtained once formulations were tested in the production scale capsule filling machine were even better: for both formulations the Relative Standard Deviation was confirmed below 3%.

Discussion and conclusion

As proven by this study, a major advantage of using the dosator technology for processing low-dose Dry Powder Inhalers is that the system can dose very small amounts of powders into capsule. This powder dosing technology does not require powder compaction to transfer the powder to the capsule. This ensures that the powder within the capsule is less likely to form aggregates and is maintained as a free-flowing powder. Maintaining the free-flowing properties of the dispended powder within the capsule better ensures the release of powder from the capsule into the inhaler when the capsule is pierced, thereby better controlling both the emitted dose and the fine particle fraction of the dose discharged from the DPI.